Altshuler Shaham Ltd Trims Stake in Eli Lilly and Company (NYSE:LLY)

Altshuler Shaham Ltd decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,319 shares of the company’s stock after selling 29 shares during the quarter. Eli Lilly and Company accounts for approximately 0.6% of Altshuler Shaham Ltd’s portfolio, making the stock its 11th largest holding. Altshuler Shaham Ltd’s holdings in Eli Lilly and Company were worth $11,261,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Lipe & Dalton purchased a new position in Eli Lilly and Company in the fourth quarter valued at $26,000. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $27,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company during the third quarter worth approximately $36,000. Family CFO Inc purchased a new position in Eli Lilly and Company during the third quarter worth approximately $40,000. Finally, O Brien Wealth Partners LLC grew its holdings in Eli Lilly and Company by 70.5% in the fourth quarter. O Brien Wealth Partners LLC now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.4 %

Eli Lilly and Company stock traded down $3.45 during trading on Thursday, hitting $771.55. The company’s stock had a trading volume of 2,169,264 shares, compared to its average volume of 3,068,803. The stock’s fifty day moving average is $761.56 and its 200 day moving average is $675.58. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The stock has a market capitalization of $733.28 billion, a price-to-earnings ratio of 113.63, a P/E/G ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.